Antidepressants - Auvelity® (dextromethorphan/bupropion), Trintellix (vortioxetine) and Fetzima® (levomilnacipran) - Step Therapy - UnitedHealthcare Commercial Plansopen_in_new
Step therapy program requiring trials of lower-cost/default antidepressants prior to coverage of Auvelity (dextromethorphan/bupropion), Trintellix (vortioxetine), or Fetzima (levomilnacipran) for UnitedHealthcare Commercial Plans. Defines required prior trials, exceptions for inpatient initiation and new-plan members, duration of authorization, and use of claims history for auto-approval.
Added Auvelity to program (3/2023).
Annual reviews and updated references recorded (10/2024, 10/2025).
Requirement to document duration of medication trial in addition to name and date (5/2017).
Added self-look back for auto adjudication (5/2019).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.